Simultaneous Suppression of Epidermal Growth Factor Receptor and c-erbB-2 Reverses Aneuploidy and Malignant Phenotype of a Human Ovarian Carcinoma Cell Line

Cancer Research

Volumn 64, Issue 3, 2004, Pages 789-794

  Pack, Svetlana D ^a   Alper, Özgül M ^d   Stromberg, Kurt ^b   Augustus, Meena ^c   Özdemirli, Metin ^d   Miermont, Anne M ^d   Klus, Greg ^d   Rusin, Marek ^c   Slack, Rebecca ^d   Hacker, Neville F ^e   Ried, Thomas ^c   Szallasi, Zoltan ^f   Alper, Özge ^d,g  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e ROYAL HOSPITAL FOR WOMEN   (Australia)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ANEUPLOIDY; ARTICLE; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CARCINOMA CELL; CELL DEATH; COLONY FORMATION; CYTOGENETICS; EXPRESSION VECTOR; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC TRANSFECTION; GENOTYPE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; ONCOGENE C ERB; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL;

ANEUPLOIDY; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DINOPROSTONE; DNA, ANTISENSE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRANSFECTION;

EID: 10744229645     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1982     Document Type: Article

References (20)

1. Harlozinska, A., Bar, J. K., Sobanska, E., and Goluda, M. Epidermal growth factor receptor and c-erbB-2 oncoproteins in tissue and tumor effusion cells of histopathologically different ovarian neoplasms. Tumour Biol., 19: 364-373, 1998.
2. Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., and Arteaga, C. L. Epidermal growth factor receptor (HERI) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res., 61: 8887-8895, 2001.
3. Normanno, N., Campiglio, M., De, L. A., Somenzi, G., Maiello, M., Ciardiello, F., Gianni, L., Salomon, D. S., and Menard, S. Cooperative inhibitory effect of ZD 1839 (lressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol., 13: 65-72, 2002.
4. Alper, O., De, Santis, M. L., Stromberg, K., Hacker, N. F., Cho-Chung, Y. S., and Salomon, D. S. Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cells. Int. J. Cancer, 88: 566-574, 2000.
5. Pegues, J. C., and Stromberg, K. Inducible antisense inhibition of erbB-2 expression reduces anchorage independent growth of ovarian carcinoma cells. Cancer Lett., 117: 73-79, 1997.
6. Kallioniemi, A., Kallioniemi, O. P., Sudar, D., Rutovitz, D., Gray, J. W., Waldman, F., and Pinkel, D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science (Wash. DC), 258: 818-821, 1992.
7. Tsao, S. W., Wong, N., Wang, X., Liu, Y., Wan, T. S., Fung, L. F., Lancaster, W. D., Gregoire, L., and Wong, Y. C. Nonrandom chromosomal imbalances in human ovarian surface epithelial cells immortalized by HPV16-E6E7 viral oncogenes. Cancer Genet. Cytogenet., 130: 141-149, 2001.
8. Abeysinghe, H. R., Cedrone, E., Tyan, T., Xu, J., and Wang, N. Amplification of C-MYC as the origin of the homogeneous staining region in ovarian carcinoma detected by micro-FISH. Cancer Genet. Cytogenet., 114: 136-143, 1999.
9. Bayani, J., Brenton, J. D., Macgregor, P. F., Beheshti, B., Albert, M., Nallainathan, D., Karaskova, J., Rosen, B., Murphy, J., Laframboise, S., Zanke, B., and Squire, J. A. Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res., 62: 3466-3476, 2002.
10. Anand, N., Murthy, S., Amann, G., Wernick, M., Porter, L. A., Cukier, I. H., Collins, C., Gray, J. W., Diebold, J., Demetrick, D. J., and Lee, J. M. Protein elongation factor EEFIA2 is a putative oncogene in ovarian cancer. Nat. Genet., 31: 301-305, 2002.
11. Loukinov, D. I., Pugacheva, E., Vatolin, S., Pack, S. D., Moon, H., Chernukhin, I., Mannan, P., Larsson, E., Kanduri, C., Vostrov, A. A., Cui, H., Niemitz, E. L., Rasko, J. E., Docquier, F. M., Kistler, M., Breen, J. J., Zhuang, Z., Quitschke, W. W., Renkawitz, R., Klenova, E. M., Feinberg, A. P., Ohlsson, R., Morse, H. C., and Lobanenkov, V. V. Free in PMC BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc. Natl. Acad. Sci. USA, 99: 6806-6811, 2002.
12. Lassus, H., Salovaara, R., Aaltonen, L. A., and Butzow, R. Allelic analysis of serous ovarian carcinoma reveals two putative tumor suppressor loci at 18q22-q23 distal to SMAD4, SMAD2, and DCC. Am. J. Pathol., 159: 35-42, 2001.
13. Hayakawa, A., Wu, J., Kawamoto, Y., Zhou, Y. W., Tanuma, S., Nakashima, I., and Suzuki, H. Activation of caspase-8 is critical for sensitivity to cytotoxic anti-Fas antibody-induced apoptosis in human ovarian cancer cells. Apoptosis, 7: 107-113, 2002.
14. Menzin, A. W., Loret de Mola, J. R., Bilker, W. B., Wheeler, J. E., Rubin, S. C., and Feinberg, R. F. Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer: detection in ascitic fluid and localization to primary sites and metastatic implants. Cancer, 82: 152-158, 2002.
15. Berns, E. M., Klijn, J. G., Henzen-Logmans, S. C., Rodenburg, C. J., vanderBurg, M. E., and Foekens, J. A. Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer. Int. J. Cancer, 52: 218-224, 1992.
16. Sartorius, C. A., Takimoto, G. S., Richer, J. K., Tung, L., and Horwitz, K. B. Association of the Ku autoantigen/DNA-dependent protein kinase holoenzyme and poly(ADP-ribose) polymerase with the DNA binding domain of progesterone receptors. J. Mol. Endocrinol., 24: 165-182, 2000.
17. Munstedt, K., Steen, J., Knauf, A. G., Buch, T., von Georgi, R., and Franke, F. E. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer (Phila.), 89: 1783-1791, 2000.
18. Smith, S., and de Lange, T. Cell cycle dependent localization of the telomeric PARP, tankyrase, to nuclear pore complexes and centrosomes. J. Cell. Sci., 112: 3649-3656, 1999.
19. Pirrotta, V. Transcription. Puffing with PARP. Science, 299: 528-529, 2003.
20. Munkarah, A. R., Morris, R., Baumann, P., Deppe, G., Malone, J., Diamond, M. P., and Saed, G. M. Effects of prostaglandin E(2) on proliferation and apoptosis of epithelial ovarian cancer cells. J. Soc. Gynecol. Investig., 9: 168-173, 2002.